AHA 2021 This remote hypertension and LDL-c management program enrolled over 10,000 patients at high CV risk. The program effectively improved hypertension and LDL-c control across a diverse health care network.
AHA 2021 Alexander Blood talks about the design of a remote algorithm-based program for hypertension and lipid management and shares the outcomes of the first 10,000 patients enrolled in this program.
AHA 2021 Prof. Ferdinand summarizes and discusses the results from the Chinese Rural Hypertension Control (CRHC) Project.
AHA 2021 In a cluster trial of villages, BP control was significantly improved by a village doctor-led intervention for hypertension treatment compared to usual care among hypertensive residents in rural China.
ESC 2021 The QUARTET trial showed that starting with a quarter-dose quadruple combination pill led to greater BP lowering compared to starting with standard dose monotherapy in patients with hypertension.
ESC 2021 The STEP study showed that intensive BP lowering (SBP target 110 to <130 mmHg) reduced the risk of CV events in older patients with hypertension, compared to standard treatment (SBP target 130 to <150 mmHg).
ESC 2021 The Salt Substitute and Stroke Study (SSaSS) showed that replacement of salt (100% NaCl) with a salt substitute (75% NaCl + 25% KCl) reduces the risk of stroke in people with prior stroke or hypertension.
This post-hoc analysis of PARAGON-HF suggests that sacubitril/valsartan reduces blood pressure to a greater extent than valsartan in patients with apparent resistant hypertension or apparent MRA-resistant hypertension.
The European Society of Hypertension has published a position paper on renal denervation (RDN), following the publication of five sham-controlled RCTs which provided evidence that RDN is an effective and safe option for the treatment of hypertension.
There was no difference in CV outcomes with ACEi monotherapy as first-line hypertension treatment compared to ARB monotherapy in a large-scale observational network study.
Women with hypertension stage 1 (130-139 mmHg) at their early 40s had an increased risk of ACS during midlife, while this association was non-significant in men after adjusting for CV risk factors.
ACC 2021 In patients with resistant hypertension despite on a triple medication combination daily pill, renal denervation resulted in a 4.5 mmHg greater decrease after 2 months than a sham control.